Reportable Segment — Acquired in-process research and development
Business Segments · Acquired in-process research and developmentEli Lilly Reportable Segment — Acquired in-process research and development decreased by 19.4% to $528.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 179.5%, from $189.20M to $528.80M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Acquired in-process research and development shows an upward trend with a 47.4% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ4 2025
How to read this metric
Higher levels indicate a robust strategy for pipeline expansion through M&A, though it carries higher execution risk.
Detailed definition
Reflects the costs associated with acquiring intellectual property or research projects from third parties that have not...
Peer comparison
Comparable to IPR&D charges or business development expenses in the biotech and pharma industry.
Metric ID:
lly_segment_reportable_segment_acquired_in_process_research_and_developmentHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $227.13M | $227.13M | $227.13M | $227.13M | $949.95M | $949.95M | $949.95M | $949.95M | $110.50M | $154.30M | $2.83B | $189.20M | $1.57B | $153.80M | $655.70M | $528.80M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +318.2% | +0.0% | +0.0% | +0.0% | -88.4% | +39.6% | >999% | -93.3% | +730.7% | -90.2% | +326.3% | -19.4% |
| YoY Change | — | — | — | — | +318.2% | +318.2% | +318.2% | +318.2% | -88.4% | -83.8% | +197.5% | -80.1% | >999% | -0.3% | -76.8% | +179.5% |
Range$110.50M – $2.83B
CAGR+25.3%
Avg YoY Growth+220.3%
Median YoY Growth+188.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — acquired in-process research and development?
- Eli Lilly (LLY) reported reportable segment — acquired in-process research and development of $528.80M in Q4 2025.
- How has Eli Lilly's reportable segment — acquired in-process research and development changed year-over-year?
- Eli Lilly's reportable segment — acquired in-process research and development increased by 179.5% year-over-year, from $189.20M to $528.80M.
- What is the long-term trend for Eli Lilly's reportable segment — acquired in-process research and development?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — acquired in-process research and development has grown at a 47.4% compound annual growth rate (CAGR), from $908.50M to $2.91B.
- What does reportable segment — acquired in-process research and development mean?
- Costs incurred to purchase external research and development projects that are still in progress.